{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:26Z","timestamp":1792712186691,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00520-019-04672-w","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T17:34:15Z","timestamp":1549042455000},"page":"3749-3758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-utility analysis of aprepitant for patients who truly need it in Japan"],"prefix":"10.1007","volume":"27","author":[{"given":"Ikuto","family":"Tsukiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyo","family":"Tsukiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ejiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"issue":"2","key":"4672_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00520-001-0339-7","volume":"10","author":"J Herrstedt","year":"2002","unstructured":"Herrstedt J (2002) Nausea and emesis: still an unsolved problem in cancer patients? Support Care Cancer 10(2):85\u201387. \n                    https:\/\/doi.org\/10.1007\/s00520-001-0339-7","journal-title":"Support Care Cancer"},{"issue":"10","key":"4672_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.biopsych.2004.02.007","volume":"55","author":"M Bergstrom","year":"2004","unstructured":"Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55(10):1007\u20131012. \n                    https:\/\/doi.org\/10.1016\/j.biopsych.2004.02.007","journal-title":"Biol Psychiatry"},{"issue":"7","key":"4672_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00003495-200464070-00013","volume":"64","author":"TM Dando","year":"2004","unstructured":"Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64(7):777\u2013794","journal-title":"Drugs"},{"issue":"22","key":"4672_CR4","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"issue":"12","key":"4672_CR5","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098. \n                    https:\/\/doi.org\/10.1002\/cncr.11433","journal-title":"Cancer"},{"issue":"6","key":"4672_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000\u20131006. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl019","journal-title":"Ann Oncol"},{"issue":"4","key":"4672_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431. \n                    https:\/\/doi.org\/10.1007\/s00520-009-0680-9","journal-title":"Support Care Cancer"},{"issue":"12","key":"4672_CR8","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.09.050","journal-title":"J Clin Oncol"},{"issue":"3","key":"4672_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","volume":"113","author":"W Yeo","year":"2009","unstructured":"Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529\u2013535. \n                    https:\/\/doi.org\/10.1007\/s10549-008-9957-9","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"4672_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1111\/j.1349-7006.2010.01689.x","volume":"101","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101(11):2455\u20132461. \n                    https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01689.x","journal-title":"Cancer Sci"},{"issue":"31","key":"4672_CR11","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189\u20134198. \n                    https:\/\/doi.org\/10.1200\/jco.2010.34.4614","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"4672_CR12","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"4672_CR13","unstructured":"NCCN practice guidelines in oncology. Antiemesis 2017 ver. 2. (2017). [Cited 18 August 2017.] Available from URL: \n                    https:\/\/www.nccn.org\/professionals\/physician\n                    \n                   _gls\/pdf \/ antiemesis.pdf"},{"issue":"1","key":"4672_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","volume":"21","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21(1):1\u201312. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0852-1","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"4672_CR15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cncr.27899","volume":"119","author":"DR Gomez","year":"2013","unstructured":"Gomez DR, Liao KP, Giordano S, Nguyen H, Smith BD, Elting LS (2013) Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer 119(7):1428\u20131436. \n                    https:\/\/doi.org\/10.1002\/cncr.27899","journal-title":"Cancer"},{"issue":"2","key":"4672_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2006.09.019","volume":"43","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 43(2):299\u2013307. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2006.09.019","journal-title":"Eur J Cancer"},{"issue":"1","key":"4672_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1524-4733.2006.00141.x","volume":"10","author":"S Moore","year":"2007","unstructured":"Moore S, Tumeh J, Wojtanowski S, Flowers C (2007) Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 10(1):23\u201331. \n                    https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00141.x","journal-title":"Value Health"},{"key":"4672_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","volume":"5","author":"S Humphreys","year":"2013","unstructured":"Humphreys S, Pellissier J, Jones A (2013) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 5:215\u2013224. \n                    https:\/\/doi.org\/10.2147\/CMAR.S44539","journal-title":"Cancer Manag Res"},{"issue":"8","key":"4672_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-007-0349-1","volume":"16","author":"L Annemans","year":"2008","unstructured":"Annemans L, Strens D, Lox E, Petit C, Malonne H (2008) Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 16(8):905\u2013915. \n                    https:\/\/doi.org\/10.1007\/s00520-007-0349-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"4672_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ajco.12170","volume":"10","author":"SL Chan","year":"2014","unstructured":"Chan SL, Jen J, Burke T, Pellissier J (2014) Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. Asia Pac J Clin Oncol 10(1):80\u201391. \n                    https:\/\/doi.org\/10.1111\/ajco.12170","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"4672_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.vhri.2012.03.002","volume":"1","author":"G Lopes","year":"2012","unstructured":"Lopes G, Burke T, Pellissier J, Zhang X-H, Dedhiya S, Chan A (2012) Aprepitant for patients receiving highly emetogenic chemotherapy: an economic analysis for Singapore. Value Health Reg Issues 1(1):66\u201374. \n                    https:\/\/doi.org\/10.1016\/j.vhri.2012.03.002","journal-title":"Value Health Reg Issues"},{"key":"4672_CR22","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/cas.13736","volume":"109","author":"I Tsukiyama","year":"2018","unstructured":"Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y, Ejiri M, Sakuma M, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A (2018) Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881\u20132888. \n                    https:\/\/doi.org\/10.1111\/cas.13736","journal-title":"Cancer Sci"},{"issue":"4","key":"4672_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-014-2430-x","volume":"23","author":"S Ito","year":"2015","unstructured":"Ito S, Tsukiyama I, Ando M, Katakami M, Hamanaka R, Kosaka K, Matsubara A, Nishimura M, Tanaka H, Asai N, Yokoe N, Takahashi A, Baba K, Matsuura K, Yamaguchi E, Kubo A (2015) Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it. Support Care Cancer 23(4):905\u2013912. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2430-x","journal-title":"Support Care Cancer"},{"issue":"4","key":"4672_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00002820-199708000-00005","volume":"20","author":"S Borjeson","year":"1997","unstructured":"Borjeson S, Hursti TJ, Peterson C, Fredikson M, Furst CJ, Avall-Lundqvist E, Steineck G (1997) Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs 20(4):260\u2013266","journal-title":"Cancer Nurs"},{"issue":"6","key":"4672_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF01880641","volume":"4","author":"SM Grunberg","year":"1996","unstructured":"Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea\/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4(6):435\u2013439","journal-title":"Support Care Cancer"},{"key":"4672_CR26","unstructured":"Exchange rates\u2014OECD data. [Cited 17 August 2017]. Available from URL: \n                    https:\/\/data.oecd.org\/conversion\/exchange-rates.htm"},{"issue":"4","key":"4672_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19(4):422\u2013437. \n                    https:\/\/doi.org\/10.1002\/hec.1481","journal-title":"Health Econ"},{"issue":"1","key":"4672_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/gyno.2002.6807","volume":"87","author":"CC Sun","year":"2002","unstructured":"Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87(1):118\u2013128. \n                    https:\/\/doi.org\/10.1006\/gyno.2002.6807","journal-title":"Gynecol Oncol"},{"issue":"17","key":"4672_CR29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/jnci\/djs335","volume":"104","author":"LV Santos dos","year":"2012","unstructured":"dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104(17):1280\u20131292. \n                    https:\/\/doi.org\/10.1093\/jnci\/djs335","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4672_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.1987.5.1.141","volume":"5","author":"F Roila","year":"1987","unstructured":"Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, DiCostanzo F, Donati D, Ballatori E, Tognoni G et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5(1):141\u2013149. \n                    https:\/\/doi.org\/10.1200\/jco.1987.5.1.141","journal-title":"J Clin Oncol"},{"issue":"5","key":"4672_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","volume":"64","author":"CF Pollera","year":"1989","unstructured":"Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117\u20131122","journal-title":"Cancer"},{"issue":"2\u20133","key":"4672_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","volume":"28","author":"A Bois du","year":"1992","unstructured":"du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 28(2\u20133):450\u2013457","journal-title":"Eur J Cancer"},{"issue":"9","key":"4672_CR33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9):1171\u20131177. \n                    https:\/\/doi.org\/10.1007\/s00520-009-0737-9","journal-title":"Support Care Cancer"},{"issue":"6","key":"4672_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19(6):807\u2013813. \n                    https:\/\/doi.org\/10.1007\/s00520-010-0899-5","journal-title":"Support Care Cancer"},{"issue":"6","key":"4672_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104(6):711\u2013717. \n                    https:\/\/doi.org\/10.1111\/cas.12146","journal-title":"Cancer Sci"},{"issue":"6","key":"4672_CR36","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28(6):1260\u20131267. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"},{"issue":"11","key":"4672_CR37","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1248\/bpb.b16-00440","volume":"39","author":"N Mukoyama","year":"2016","unstructured":"Mukoyama N, Yoshimi A, Goto A, Kotani H, Ishikawa K, Miyazaki N, Miyazaki M, Yamada K, Kikkawa F, Hasegawa Y, Ozaki N, Noda Y (2016) An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in Japanese subjects. Biol Pharm Bull 39(11):1852\u20131858. \n                    https:\/\/doi.org\/10.1248\/bpb.b16-00440","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"4672_CR38","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00520-018-4120-6","volume":"26","author":"S Puri","year":"2018","unstructured":"Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26(8):2911\u20132918. \n                    https:\/\/doi.org\/10.1007\/s00520-018-4120-6","journal-title":"Support Care Cancer"},{"issue":"3","key":"4672_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/qjmed\/92.3.177","volume":"92","author":"MK Campbell","year":"1999","unstructured":"Campbell MK, Torgerson DJ (1999) Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. Q J Med 92(3):177\u2013182. \n                    https:\/\/doi.org\/10.1093\/qjmed\/92.3.177","journal-title":"Q J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04672-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T19:05:08Z","timestamp":1580497508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04672-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4672"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04672-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}